About Ensoma
Ensoma is a company based in Boston (United States) founded in 2019. Ensoma has raised $205 million across 3 funding rounds from investors including ARE, Mirae Asset and Takeda Pharmaceuticals. The company has 52 employees. Ensoma has completed 1 acquisition, including Twelve Bio. Ensoma offers products and services including HSC Engineering Platform and In Vivo Treatments. Ensoma operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Boston, United States
- Employees 52
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website ensoma.com
- Social LinkedIn X
- Legal Name Ensoma, Inc.
- Total Equity Funding$205M (USD)
in 3 rounds
- Latest Funding Round$50M (USD), Series B
May 2023
- InvestorsARE
& 19 more
- Employee Count52
- Investments & Acquisitions
Products & Services of Ensoma
Ensoma offers a comprehensive portfolio of products and services, including HSC Engineering Platform and In Vivo Treatments.
Platform for in vivo engineering of stem cells to treat diseases.
One-time therapies targeting genetic and immune disorders.
Funding Insights of Ensoma
Ensoma has successfully raised a total of $205M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $205M
- Total Rounds 3
- Last Round Series B — $50M
- First Round $70M
(Feb 2021)
- Investors Count 20
All 3 funding rounds of Ensoma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $50M | Series B | – | – | |
| Jan 2023 | $85M | Series B | – | Arix Bioscience, 5AM Ventures | |
| Feb 2021 | $70M | Series A | – | 5AM Ventures |
20 investors in total: 20 institutional.
Investors in Ensoma
Ensoma has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Mirae Asset and Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A venture capital firm focused on biotechnology innovations. | – | bioluminescence.com | San Francisco, United States | |
Delos Capital is engaged in private equity and financial advisory services. | – | deloscap.com | New York City, United States | |
Investments in healthcare companies are made by SymBiosis. | – | symbiosis.vc | Bentonville, United States | |
Venture capital fund backed incubator focused on the healthcare startups | – | 5amventures.com | San Francisco, United States | |
Investments in biotech startups are made by Arix Bioscience. | 2016 | arixbioscience.com | London, United Kingdom | |
Venture capital is provided to biomedical technology startups. | – | cataliocapital.com | New York, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | – | fprimecapital.com | - | |
Venture capital firm focused on healthcare startups | – | solasta-ventures.com | Boston, United States | |
- | – | takedaventures.com | - | |
Private investment firm focused on multiple sectors | – | vikingglobal.com | Greenwich, United States |
Investor details for Ensoma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ensoma
66 people are tracked at Ensoma (23 in leadership, 13 in board & advisors, 30 in team); the tracked headcount is 52.
| Name | Role | Group |
|---|---|---|
Jim Burns | Chief Executive Officer and Board Member | Leadership |
Patrick Au | VP, Translational Research & Early Development | Leadership |
Robert Peters | Chief Scientific Officer | Leadership |
Stephanie Fedak | VP, Human Resources | Leadership |
Andrew Dietz | Vice President, Head Of Clinical Research & Development | Leadership |
Betsy Bogard | Head of Program & Alliance Management | Leadership |
Antonia Katsiris | Associate Director, Human Resources | Leadership |
John Desimone | VP, Finance | Leadership |
Stefano Stella | VP, Gene Editing | Leadership |
Pauline Rimmelé | Director, Biology | Leadership |
Shreya Kulkarni | Associate Director | Leadership |
Claire Stingley | Director, Lab And Facilities Operations | Leadership |
Dawn Houlihan | Head, Quality | Leadership |
Daniel Leblanc | Chief Technology Officer | Leadership |
Jon Garen | Chief Corporate Development Officer | Leadership |
Christopher Plescia | Director Bioanalytical | Leadership |
Alexey Seregin | Senior Director, Platform | Leadership |
Gregory Bremer | Director Upstream Process Development | Leadership |
Anxhela Kole | Director, Downstream Process Development | Leadership |
Patrick Grumbach | Director | Leadership |
46 more people are available in the full profile.
Complete people profiles for Ensoma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ensoma
Ensoma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Twelve Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
CRISPR-Cas12a technology is applied to develop diagnostics and therapeutics. | twelve.bio | Copenhagen, Denmark | 2019 | Jan 2023 | •••• |
Complete acquisition details for Ensoma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Ensoma
4 dated milestones of Ensoma across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Ensoma is founded.
- Funding First funding round of $70.0M.
- Acquisition Acquires Twelve Bio.
- Funding Latest funding round, Series B, of $50.0M.
Competitors of Ensoma
Ensoma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| editasmedicine.com | 2013 | Cambridge, United States | $210M | 257 | Therapeutics for rare genetic diseases are developed using CRISPR technology. |
Detailed competitors of Ensoma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ensoma
The website of Ensoma (ensoma.com) receives about 2.8K visits a month and ranks #4,644,561 among all websites worldwide, #5,536 in Biotechnology and Pharmaceuticals.
- Monthly visits2.8K
▼ 24% vs previous month
- Unique visitors1.6K
per month
- Global rank#4,644,561
among all websites
- Category rank#5,536
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.7
- Average visit35 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Ensoma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| servier.us | 100% | – | #2,050,491 | View details | |
| pieris.com | 100% | – | – | View details | |
| paratekpharma.com | 99% | 4K | #5,533,702 | View details | |
| praxismedicines.com | 99% | 35.6K | #1,244,570 | View details | |
| vedantabio.com | 97% | 5.6K | #3,168,764 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 23 similar websites and full traffic analytics for Ensoma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 23 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Ensoma
Complete news archive for Ensoma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Ensoma
10 companies that operate in the same segment as Ensoma (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ensoma
Ensoma was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Ensoma is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Ensoma is a funded company, having raised a total of $205M across 3 funding rounds to date. The company's 1st funding round was a Series A of $70M, raised on Feb 2021.
Ensoma has 52 employees.
Ensoma was founded in 2019 and is based in Boston, United States. Operations focus on biotechnology, specifically in vivo modification of hematopoietic stem cells and other immune cells using engineered adenovirus vectors known as Engenious. These vectors enable delivery of genome modification technologies for treating myeloablative conditions through a single injection. Services target applications in T cells, B cells, and myeloid cells within the therapeutic sector.
Ensoma's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Ensoma offers HSC Engineering Platform and In Vivo Treatments.
Ensoma has made 1 acquisition, including Twelve Bio.
Ensoma has 20 investors. Key investors include ARE, Mirae Asset, Takeda Pharmaceuticals, Kite Pharma, and Fred Hutch.
Ensoma operates through Ensoma, Inc..